We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Panretinal Photocoagulation vs Anti–Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy

Simar Rajan Singh, MS1; Ramandeep Singh, MS1
[+] Author Affiliations
1Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
JAMA Ophthalmol. 2016;134(6):715-716. doi:10.1001/jamaophthalmol.2016.0701.
Text Size: A A A
Published online


To the Editor In their Viewpoint, Gross and Glassman1 have concluded that intravitreal anti–vascular endothelial growth factor (anti-VEGF) is noninferior to panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy (PDR). We have a few concerns about this approach of using anti-VEGF for PDR.

In the study by the Diabetic Retinopathy Clinical Research Network2 on which this Viewpoint is based, worsening of fibrosis was included as a failure criterion in the anti-VEGF group and PRP could be performed in such eyes at investigator discretion. The investigators reported that at least 12 eyes (6%) required secondary PRP in the anti-VEGF group, for which 8 PRP treatments were done during vitrectomy. However, the baseline characteristics, causes for vitrectomy, and final outcome of these eyes have not been separately analyzed.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2016
Jeffrey G. Gross, MD; Adam R. Glassman, MS
1Carolina Retina Center, Columbia, South Carolina
2Jaeb Center for Health Research, Tampa, Florida
JAMA Ophthalmol. 2016;134(6):716. doi:10.1001/jamaophthalmol.2016.0703.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...